期刊文献+

甲磺酸阿帕替尼三线治疗老年晚期胃癌的临床效果及对生活质量的影响分析 被引量:4

下载PDF
导出
摘要 目的分析甲磺酸阿帕替尼三线治疗老年晚期胃癌的临床效果及对生活质量的影响。方法 64例老年晚期胃癌患者,依据随机原则分为研究组和参照组,每组32例。参照组患者应用常规支持治疗,研究组患者在参照组基础上联合甲磺酸阿帕替尼三线治疗。对比两组患者治疗效果和生活质量好转情况。结果研究组患者的治疗总有效率93.75%显著高于参照组的68.75%,差异具有统计学意义(P<0.05)。研究组患者的生活质量好转率93.75%(30/32)显著高于参照组的71.88%(23/32),差异具有统计学意义(P<0.05)。结论老年晚期胃癌应用甲磺酸阿帕替尼三线治疗可提升临床疗效,患者的生存状况得以改善,具有较高的耐受性。
作者 邹惠笑
出处 《中国实用医药》 2019年第18期91-92,共2页 China Practical Medicine
  • 相关文献

参考文献10

二级参考文献43

  • 1Kadokawa Y, Sonoda K, Nakajima S, Kawabe A, Egawa H. [Advanced gastric cancer in an elderly woman showing histopathologic CR after a course of S-1 and CDDP combination therapy]. Gan To Kagaku Ryoho ,2010, 37:711-713 [PMID: 20414032].
  • 2Akaza H, Kawai K, Tsuruo T, Tsukagoshi S, Aiba K, Shimada Y, Kakeji Y, Ishikawa H, Ikeda T, Nakamura S, Tamura T, Yamamoto N, Isonishi S, Hinotsu S, Hirose M, Katsura J. [Future directions of anticancer drug development in Japan]. Gan To Kagaku Ryoho ,2008, 35:351-360 [PMID: 18281781].
  • 3Kozloff M, Yood MU, Berlin J, Flynn PJ, Kabbinavar FF, Purdie DM, Ashby MA, DongW, Sugrue MM, Grothey A. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist ,2009, 14:862-870 [PMID: 19726453 DOI: 10.1634/ theoncologist.,2009-0071].
  • 4Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell ,2011, 144:646-674 [PMID: 21376230 DOI: 10.1016/j.cell.,2011.02.013].
  • 5Olsson AK, Dimberg A, Kreuger J, Claesson- Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol ,2006, 7: 359-371 [PMID: 16633338].
  • 6Holmes K, Roberts OL, Thomas AM, Cross MJ. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell Signal ,2007, 19:,2003-,2012 [PMID: 17658244].
  • 7Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature ,2005, 438:967-974 [PMID: 16355214|.
  • 8Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol ,2011, 29:3968-3976 [PMID: 21844504 DOI: 10.1200/JCO.,2011.36.2236].
  • 9Li J, Zhao X, Chen L, Guo H, Lv F, Jia K, Yv K, Wang F, Li C, Qian J, Zheng C, Zuo Y. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer ,2010, 10:529 [PMID: 20923544 DOI: 10.1186/1471-2407-10-529].
  • 10Tian S, Quan H, Xie C, Guo H, Lti F, Xu Y, Li J, Lou L. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci ,2011, 102:1374-1380 [PMID: 21443688 DOI: 10.1111/ j.1349-7006.,2011.01939.x].

共引文献211

同被引文献42

引证文献4

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部